Skip to content

The Role of specialized therapeutic contact lens with antibiotic drugs in the treatment of bacterial corneal infection.

PROSPECTIVE, RANDOMIZED STUDY OF USING THE HYPER-CL LENS IN SUBJECTS SUFFERING FROM BACTERIAL KERATITIS - HCL Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027088
Enrollment
40
Registered
2020-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H160- Corneal ulcer

Interventions

Intervention1: Hyper-CL Lens: Hyper-CL lens along with Moxifloxacin 0.5% w/v topical eye drops 6 times a day till resolution of infection Control Intervention1: Antibiotics Alone: Moxifloxacin 0.5% w/

Sponsors

EyeYon Medical Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subject is 18-86 years old 2. Subject with Bacterial keratitis in one eye only 3. Subject with Bacterial Keratitis of at least grade 2 score in Average length of infiltration and in Average length of epithelial defect (1mm or above) 4. Best-corrected visual acuity of 6/60 or better in the uninvolved eye 5. No prior antibiotic treatment for current Bacterial Keratitis 6. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.

Exclusion criteria

Exclusion criteria: 1. Perforation or imminent perforation of cornea 2. Subject with glaucoma shunts (e.g. Ahmed valve) and or bleb 3. Sign of inflammation in both eyes 4. Severe itching suggesting viral infection or allergy reaction 5. Subepithelial infiltrate suggesting viral infection 6. Dendrite like ulcer or suspecting of Herpes keratitis 7. Previous penetrating keratoplasty 8. No light perception in the affected eye 9. Pregnancy 10. Other active ocular infection 11. Any infiltration suggesting other than bacterial infection e.g. parasite, fungal. 12. Any corneal transplant 13. Post refractive surgery 14. Corneal inlays 15. Any other condition which in the opinion of the investigator would place the patient at undue risk for participation. 16. Participation in another clinical study within the past 30 days

Design outcomes

Primary

MeasureTime frame
Change in Bacterial Keratitis severity scoreTimepoint: 14th day

Secondary

MeasureTime frame
1. Time for significant improvement in Bacterial Keratitis severity score (at least 2 points decrease) 2. Change in Bacterial Keratitis score over time 3. Change from baseline in Pain score over time 4. Change in Visual Acuity over timeTimepoint: 1st day, 2nd day, 3rd day, 5th day and 14th day

Countries

India

Contacts

Public ContactProf A Heber

Dr. Agarwals Eye Hospital

drlionalraj@dragarwal.com8754411261

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 11, 2026